Updated Jul 16, 2026
Feider Stephen has filed 3 SEC Form 4 filings across 1 company in the last 90 days — selling. Lifetime open-market sales: $1.31M.
Stephen Feider serves as the Chief Financial Officer of Beta Bionics, Inc., a medical device company focused on improving diabetes treatment. He has filed multiple SEC documents related to his role but does not appear to have significant public recognition.
| Role | Insider |
|---|---|
| Notability | 20/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-07-02 | BBNX | Beta Bionics, Inc. | S — Open-market sale | 4.9K | $17.03 | $83K |
| 2026-07-02 | BBNX | Beta Bionics, Inc. | M — Option exercise | 4.9K | $5.10 | $25K |
| 2026-07-02 | BBNX | Beta Bionics, Inc. | S — Open-market sale | 5.1K | $17.05 | $87K |
| 2026-07-02 | BBNX | Beta Bionics, Inc. | M — Option exercise | 5.1K | $5.10 | $26K |
| 2026-06-30 | BBNX | Beta Bionics, Inc. | S — Open-market sale | 4.9K | $17.03 | $83K |
| 2026-06-30 | BBNX | Beta Bionics, Inc. | M — Option exercise | 4.9K | $5.10 | $25K |
| 2026-06-30 | BBNX | Beta Bionics, Inc. | S — Open-market sale | 5.1K | $17.05 | $87K |
| 2026-06-30 | BBNX | Beta Bionics, Inc. | M — Option exercise | 5.0K | $5.10 | $25K |
| 2026-06-03 | BBNX | Beta Bionics, Inc. | S — Open-market sale | 6.7K | $12.61 | $84K |
| 2026-03-03 | BBNX | Beta Bionics, Inc. | S — Open-market sale | 1.4K | $12.36 | $18K |
| 2026-03-03 | BBNX | Beta Bionics, Inc. | A — Grant or award | 131.5K | $0.00 | |
| 2025-12-04 | BBNX | Beta Bionics, Inc. | S — Open-market sale | 1.4K | $29.34 | $42K |
| 2025-10-03 | BBNX | Beta Bionics, Inc. | S — Open-market sale | 1.2K | $22.28 | $26K |
| 2025-10-03 | BBNX | Beta Bionics, Inc. | S — Open-market sale | 3.8K | $21.52 | $82K |
| 2025-10-03 | BBNX | Beta Bionics, Inc. | M — Option exercise | 5.0K | $5.10 | $25K |
| 2025-10-01 | BBNX | Beta Bionics, Inc. | S — Open-market sale | 100 | $21.08 | $2K |
| 2025-10-01 | BBNX | Beta Bionics, Inc. | S — Open-market sale | 14.9K | $20.76 | $310K |
| 2025-10-01 | BBNX | Beta Bionics, Inc. | M — Option exercise | 15.0K | $5.10 | $77K |
| 2025-09-08 | BBNX | Beta Bionics, Inc. | S — Open-market sale | 9.9K | $21.13 | $209K |
| 2025-09-08 | BBNX | Beta Bionics, Inc. | M — Option exercise | 9.9K | $5.10 | $50K |
Stephen Feider serves as the Chief Financial Officer of Beta Bionics, Inc., a medical device company focused on improving diabetes treatment. He has filed multiple SEC documents related to his role but does not appear to have significant public recognition.…
3 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 16 open-market sales ($1.31M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Feider Stephen profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.